Economic model of albumin infusion in septic shock: The EMAISS study.

Bertrand GuidetIdir GhoutJacques RopersPhilippe Aegerter

Published in: Acta anaesthesiologica Scandinavica (2020)

Based on the risk reduction observed in the septic shock subgroup analysis of the ALBIOS dataset, the application of the ALBIOS trial results to Cub-Réa data may suggest that albumin infusion is likely cost-effective in septic shock.

Keyphrases

septic shock
low dose

phase iii
electronic health record

randomized controlled trial
phase ii

double blind
placebo controlled